title: [Developmental status of new antituberculous drugs].
abstract: Worldwide, there are nearly 9 million new cases of active tuberculosis (TB) and 1.8 million associated deaths every year. Especially, difficulty of the chemotherapy in TB/HIV co-infection and also prevalence of multi drug-resistant tuberculosis (MDR-TB) as well as extensively drug-resistant tuberculosis (XDR-TB) make serious clinical problems. Development of the new drugs is essential to overcome of such clinical difficulty as described above. The developmental status of the new drugs has at present advanced greatly by the leading contribution of the international organization such as Global Alliance for TB Drug Development and Stop TB Partnership in this decade. This article reviews the developing new compounds at presents as the key drugs for treatment of TB now.
authors.affiliation: Institute of Microbial Chemistry.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Igarashi
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Takahashi
mesh_terms: D000995:Antitubercular Agents; D015195:Drug Design; D006801:Humans; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy
chemical_list: D000995:Antitubercular Agents